IDYA

IDEAYA Biosciences, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

IDEAYA Biosciences is rapidly approaching a commercial inflection point, anchored by the clinical success of its lead candidate, darovasertib.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic clinical headlines, IDEAYA's financial trajectory reveals a precarious reliance on a dwindling cash pile and a singular lead asset.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every IDYA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between clinical triumph and financial exhaustion. The positive data for darovasertib and the resulting NDA trajectory provide a clear path to value creation, but the accelerating operational losses create a ticking clock for management. The shift toward non-dilutive revenue via the Servier agreement is a positive strategic pivot, yet it remains a one-time infusion rather than a sustainable business model until commercial products hit the market. Ultimately, the impact of this filing is a narrowing of the risk-reward window. The clinical risk is decreasing as darovasertib moves toward approval, but the financial risk is increasing as the burn rate accelerates to support a broader ADC pipeline. Investors must weigh the high-probability success of the lead asset against the systemic risk of a pre-revenue biotech with a finite cash runway and a history of partner exits.

Selected Quarter

Core Takeaway

IDYA is transitioning from clinical validation to regulatory submission, but accelerating R&D spend is shortening its cash runway.

Investor Lens

The trade-off between the high-conviction lead asset's success and the systemic risk of a pre-revenue burn rate.

Watch Next

NDA submission for darovasertib in H2 2026 and ASCO 2026 data presentations.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

bearishMay 5

Operating losses increased 28% year-over-year to $108.5 million.

margin compression

70%

neutralMay 5

Maintains an ATM program with $156.6 million in remaining capacity.

capital raise

40%

bullishMay 5

Secured landmark international licensing deal with Servier including $210M upfront.

acquisition

80%

Filing History

10-QMay 5, 2026

Expand Sequence

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.